speb/financial-data huggingface dataset:
RXRX cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 36494000.00
RXRX income_statement (annual, 2024-12-31) — Diluted Average Shares: 274207146.00
RXRX income_statement (annual, 2024-12-31) — Diluted EPS: -1.69
RXRX income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -463661000.00
RXRX income_statement (annual, 2024-12-31) — EBIT: -463216000.00
RXRX income_statement (annual, 2024-12-31) — EBITDA: -426722000.00
RXRX cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -3406000.00
RXRX cash_flow (annual, 2024-12-31) — End Cash Position: 603024000.00
RXRX cash_flow (annual, 2024-12-31) — Financing Cash Flow: 304120000.00
RXRX cash_flow (annual, 2024-12-31) — Free Cash Flow: -376219000.00
RXRX cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -7637000.00
RXRX income_statement (annual, 2024-12-31) — General And Administrative Expense: 178184000.00
RXRX balance_sheet (annual, 2024-12-31) — Goodwill: 148873000.00
RXRX balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 484728000.00
RXRX balance_sheet (annual, 2024-12-31) — Gross PPE: 295884000.00
RXRX income_statement (annual, 2024-12-31) — Gross Profit: 13250000.00
RXRX income_statement (annual, 2024-12-31) — Interest Expense: 1572000.00
RXRX income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 1572000.00
RXRX income_statement (annual, 2024-12-31) — Interest Income: 15758000.00
RXRX income_statement (annual, 2024-12-31) — Interest Income Non Operating: 15758000.00
RXRX balance_sheet (annual, 2024-12-31) — Invested Capital: 1062229000.00
RXRX cash_flow (annual, 2024-12-31) — Investing Cash Flow: 260059000.00
RXRX cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 300417000.00
RXRX balance_sheet (annual, 2024-12-31) — Leases: 72727000.00
RXRX balance_sheet (quarterly, 2024-12-31) — Leases: 72727000.00
RXRX balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 67250000.00
RXRX balance_sheet (annual, 2024-12-31) — Long Term Debt: 19022000.00
RXRX balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 86272000.00
RXRX cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -4440000.00
RXRX balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 27365000.00
RXRX balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 27365000.00
RXRX cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 277104000.00
RXRX cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 300417000.00
RXRX income_statement (annual, 2024-12-31) — Net Income: -463661000.00
RXRX income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -463661000.00
RXRX income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -463661000.00
RXRX income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -463661000.00
RXRX income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -463661000.00
RXRX cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -463661000.00
RXRX income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -463661000.00
RXRX cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -3350000.00
RXRX income_statement (annual, 2024-12-31) — Net Interest Income: 14186000.00
RXRX cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 0.00
RXRX cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -4440000.00
RXRX cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -4440000.00
RXRX income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 14186000.00
RXRX balance_sheet (annual, 2024-12-31) — Net PPE: 233213000.00
RXRX cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -13695000.00
RXRX balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 550054000.00
RXRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 1934000.00
RXRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 135340000.00
RXRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 118765000.00
RXRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 1934000.00
RXRX balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 16575000.00
RXRX income_statement (annual, 2024-12-31) — Normalized EBITDA: -426722000.00
RXRX income_statement (annual, 2024-12-31) — Normalized Income: -463661000.00
RXRX cash_flow (annual, 2024-12-31) — Operating Cash Flow: -359174000.00
RXRX income_statement (annual, 2024-12-31) — Operating Income: -479004000.00
RXRX income_statement (annual, 2024-12-31) — Operating Revenue: 58488000.00
RXRX balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 396802394.00
RXRX balance_sheet (annual, 2024-12-31) — Other Current Assets: 38107000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 8425000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -7637000.00
RXRX income_statement (annual, 2024-12-31) — Other Gand A: 178184000.00
RXRX income_statement (annual, 2024-12-31) — Other Income Expense: 30000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 335855000.00
RXRX cash_flow (annual, 2024-12-31) — Other Non Cash Items: 32955000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 14454000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 4732000.00
RXRX income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 30000.00
RXRX income_statement (annual, 2024-12-31) — Other Operating Expenses: -351000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Properties: 193078000.00
RXRX balance_sheet (annual, 2024-12-31) — Other Receivables: 49166000.00
RXRX balance_sheet (annual, 2024-12-31) — Payables: 21613000.00
RXRX balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 52632000.00
RXRX balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 50853000.00
RXRX balance_sheet (annual, 2024-12-31) — Prepaid Assets: 29601000.00
RXRX income_statement (annual, 2024-12-31) — Pretax Income: -464788000.00
RXRX cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 8143000.00
RXRX balance_sheet (annual, 2024-12-31) — Properties: 0.00
RXRX balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
RXRX cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
RXRX cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -3350000.00
RXRX cash_flow (annual, 2024-12-31) — Purchase Of Investment: 0.00
RXRX cash_flow (annual, 2024-12-31) — Purchase Of PPE: -13695000.00
RXRX balance_sheet (annual, 2024-12-31) — Receivables: 49166000.00
RXRX income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 45238000.00
RXRX income_statement (annual, 2024-12-31) — Reconciled Depreciation: 36494000.00
RXRX cash_flow (annual, 2024-12-31) — Repayment Of Debt: -4440000.00
RXRX income_statement (annual, 2024-12-31) — Research And Development: 314421000.00
RXRX balance_sheet (annual, 2024-12-31) — Restricted Cash: 3045000.00
RXRX balance_sheet (annual, 2024-12-31) — Retained Earnings: -1431283000.00
RXRX cash_flow (annual, 2024-12-31) — Sale Of Business: 277104000.00
RXRX cash_flow (quarterly, 2024-12-31) — Sale Of Business: 277104000.00
RXRX cash_flow (annual, 2024-12-31) — Sale Of Investment: 0.00
RXRX cash_flow (quarterly, 2024-12-31) — Sale Of Investment: 0.00
RXRX income_statement (annual, 2024-12-31) — Selling General And Administration: 178184000.00
RXRX balance_sheet (annual, 2024-12-31) — Share Issued: 396802394.00
RXRX cash_flow (annual, 2024-12-31) — Stock Based Compensation: 81688000.00
RXRX balance_sheet (annual, 2024-12-31) — Stockholders Equity: 1034782000.00
RXRX balance_sheet (annual, 2024-12-31) — Tangible Book Value: 550054000.00
RXRX income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (annual, 2024-12-31) — Tax Provision: -1127000.00
RXRX income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
RXRX balance_sheet (annual, 2024-12-31) — Total Assets: 1448598000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Capitalization: 1053804000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Debt: 108492000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 1034782000.00
RXRX income_statement (annual, 2024-12-31) — Total Expenses: 537492000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 413816000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 734329000.00
RXRX balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 226344000.00
RXRX income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -479004000.00
RXRX balance_sheet (annual, 2024-12-31) — Working Capital: 526797000.00
RXRX income_statement (quarterly, 2025-03-31) — +Operating Expense: 184357000.00
RXRX income_statement (quarterly, 2025-03-31) — +Total Revenue: 14818000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 25086000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 2553492000.00
RXRX cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 5956000.00
RXRX income_statement (quarterly, 2025-03-31) — Basic Average Shares: 402771972.00
RXRX income_statement (quarterly, 2025-03-31) — Basic EPS: -0.50
RXRX cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 603024000.00
RXRX cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -1832000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 67877000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Capital Stock: 4000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 500453000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 500453000.00
RXRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 40527000.00
RXRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -7270000.00
RXRX cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -131957000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 3692000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -25992000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -5760000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -9762000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Payable: 3692000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -22300000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 27131000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Receivables: 4839000.00
RXRX cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -5852000.00
RXRX cash_flow (quarterly, 2025-03-31) — Changes In Cash: -98700000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Common Stock: 4000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 933947000.00
RXRX cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 41024000.00
RXRX income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 21829000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 34345000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Assets: 584145000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 11853000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Debt: 8587000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 20440000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 39651000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 39651000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 141981000.00
RXRX cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -419000.00
RXRX cash_flow (quarterly, 2025-03-31) — Deferred Tax: -419000.00
RXRX cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 19331000.00
RXRX cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 19331000.00
RXRX income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 402771972.00
RXRX income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.50
RXRX income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — EBIT: -202137000.00
RXRX income_statement (quarterly, 2025-03-31) — EBITDA: -182806000.00
RXRX cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 4833000.00
RXRX cash_flow (quarterly, 2025-03-31) — End Cash Position: 509157000.00
RXRX cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 40527000.00
RXRX cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -133789000.00
RXRX cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of Business: 4502000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 14145000.00
RXRX income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 54650000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Goodwill: 158112000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 493902000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Gross PPE: 204777000.00
RXRX income_statement (quarterly, 2025-03-31) — Gross Profit: -7011000.00
RXRX income_statement (quarterly, 2025-03-31) — Interest Expense: 508000.00
RXRX income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 508000.00
RXRX income_statement (quarterly, 2025-03-31) — Interest Income: 5558000.00
RXRX income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 5558000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Invested Capital: 958980000.00
RXRX cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -7270000.00
RXRX cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 41024000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 56024000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 16446000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 72470000.00
RXRX cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -2047000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -4438000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 41024000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -202487000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -202487000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -202487000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: 0.00
RXRX income_statement (quarterly, 2025-03-31) — Net Interest Income: 5050000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -1000000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -2047000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -2047000.00
RXRX income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 5050000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Net PPE: 204777000.00
RXRX cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -1832000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 440045000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 2003000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 152046000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 129609000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 2003000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 22437000.00
RXRX income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -182806000.00
RXRX income_statement (quarterly, 2025-03-31) — Normalized Income: -202487000.00
RXRX cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -131957000.00
RXRX cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 4502000.00
RXRX income_statement (quarterly, 2025-03-31) — Operating Income: -191368000.00
RXRX income_statement (quarterly, 2025-03-31) — Operating Revenue: 14818000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 406410733.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 32023000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 8587000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 14145000.00
RXRX income_statement (quarterly, 2025-03-31) — Other Gand A: 54650000.00
RXRX income_statement (quarterly, 2025-03-31) — Other Income Expense: -16327000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 335790000.00
RXRX cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 10954000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 20407000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 4790000.00
RXRX income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -16327000.00
RXRX income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 73000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Properties: 204777000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Other Receivables: 46124000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Payables: 25086000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 59431000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 22459000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 2470000.00
RXRX income_statement (quarterly, 2025-03-31) — Pretax Income: -202645000.00
RXRX cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 1550000.00
RXRX cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -4438000.00
RXRX cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: 0.00
RXRX cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -1000000.00
RXRX cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -1832000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Receivables: 46124000.00
RXRX income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 21829000.00
RXRX income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 19331000.00
RXRX cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -2047000.00
RXRX income_statement (quarterly, 2025-03-31) — Research And Development: 129634000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 3075000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1633694000.00
RXRX income_statement (quarterly, 2025-03-31) — Selling General And Administration: 54650000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Share Issued: 406410733.00
RXRX cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 36058000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 933947000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 440045000.00
RXRX income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (quarterly, 2025-03-31) — Tax Provision: -158000.00
RXRX income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Assets: 1305234000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 950393000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Debt: 92910000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 933947000.00
RXRX income_statement (quarterly, 2025-03-31) — Total Expenses: 206186000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 371287000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 721089000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 229306000.00
RXRX income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -191368000.00
RXRX balance_sheet (quarterly, 2025-03-31) — Working Capital: 442164000.00
RXRX income_statement (quarterly, 2025-06-30) — +Operating Expense: 175169000.00
RXRX income_statement (quarterly, 2025-06-30) — +Total Revenue: 19103000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 19314000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 2681111000.00
RXRX cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: 0.00
RXRX income_statement (quarterly, 2025-06-30) — Basic Average Shares: 417361147.00
RXRX income_statement (quarterly, 2025-06-30) — Basic EPS: -0.41
RXRX cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 509157000.00
RXRX cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -5308000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 65127000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Capital Stock: 4000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 525110000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 525110000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Cash Equivalents: 220822000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Cash Financial: 304288000.00
RXRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 97659000.00
RXRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -5808000.00
RXRX cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -76418000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -4837000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 30882000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -5148000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -13621000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Payable: -4837000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 26045000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 2470000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Receivables: 25407000.00
RXRX cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 35153000.00
RXRX cash_flow (quarterly, 2025-06-30) — Changes In Cash: 15433000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Common Stock: 4000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 919146000.00
RXRX cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 100000000.00
RXRX income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 20161000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 54835000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Assets: 587160000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 11732000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Debt: 8752000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 20484000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 39690000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 39690000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 164026000.00
RXRX cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 23849000.00
RXRX cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 23849000.00
RXRX income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 417361147.00
RXRX income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.41
RXRX income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — EBIT: -171417000.00
RXRX income_statement (quarterly, 2025-06-30) — EBITDA: -147568000.00
RXRX cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 9255000.00
RXRX cash_flow (quarterly, 2025-06-30) — End Cash Position: 533845000.00
RXRX cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 97659000.00
RXRX cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -81726000.00
RXRX cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 43620000.00
RXRX income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 46653000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Goodwill: 164270000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 505589000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Gross PPE: 193604000.00
RXRX income_statement (quarterly, 2025-06-30) — Gross Profit: -1058000.00
RXRX income_statement (quarterly, 2025-06-30) — Interest Expense: 480000.00
RXRX income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 480000.00
RXRX income_statement (quarterly, 2025-06-30) — Interest Income: 5443000.00
RXRX income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 5443000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Invested Capital: 942094000.00
RXRX cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -5808000.00
RXRX cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 100000000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 53395000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 14196000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 67591000.00
RXRX cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -2084000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: 0.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 100000000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -171897000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -171897000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -171897000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -2158000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Interest Income: 4963000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -500000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -2084000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -2084000.00
RXRX income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 4963000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Net PPE: 193604000.00
RXRX cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -3150000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 413557000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 150027000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 126243000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 23784000.00
RXRX income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -147568000.00
RXRX income_statement (quarterly, 2025-06-30) — Normalized Income: -171897000.00
RXRX cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -76418000.00
RXRX cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 0.00
RXRX income_statement (quarterly, 2025-06-30) — Operating Income: -176227000.00
RXRX income_statement (quarterly, 2025-06-30) — Operating Revenue: 19103000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 432830642.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 37338000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 8752000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 43620000.00
RXRX income_statement (quarterly, 2025-06-30) — Other Gand A: 46653000.00
RXRX income_statement (quarterly, 2025-06-30) — Other Income Expense: -633000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 341319000.00
RXRX cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 9899000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 15045000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 1565000.00
RXRX income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -633000.00
RXRX income_statement (quarterly, 2025-06-30) — Other Operating Expenses: -120000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Properties: 193604000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Other Receivables: 21606000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Payables: 19314000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 74149000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 29703000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 0.00
RXRX income_statement (quarterly, 2025-06-30) — Pretax Income: -171897000.00
RXRX cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 2743000.00
RXRX cash_flow (quarterly, 2025-06-30) — Purchase Of Business: 0.00
RXRX cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -2158000.00
RXRX cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -500000.00
RXRX cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -3150000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Receivables: 21606000.00
RXRX income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 20161000.00
RXRX income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 23849000.00
RXRX cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -2084000.00
RXRX income_statement (quarterly, 2025-06-30) — Research And Development: 128636000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Restricted Cash: 3106000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -1805589000.00
RXRX income_statement (quarterly, 2025-06-30) — Selling General And Administration: 46653000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Share Issued: 432830642.00
RXRX cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 26159000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 919146000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 413557000.00
RXRX income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (quarterly, 2025-06-30) — Tax Provision: 0.00
RXRX income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Assets: 1302355000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 933342000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Debt: 88075000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 919146000.00
RXRX income_statement (quarterly, 2025-06-30) — Total Expenses: 195330000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 383209000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 715195000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 219183000.00
RXRX income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -176227000.00
RXRX balance_sheet (quarterly, 2025-06-30) — Working Capital: 423134000.00
RXRX income_statement (quarterly, 2025-09-30) — +Operating Expense: 162498000.00
RXRX income_statement (quarterly, 2025-09-30) — +Total Revenue: 4983000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 13935000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 2980729000.00
RXRX cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 0.00
RXRX income_statement (quarterly, 2025-09-30) — Basic Average Shares: 446988046.00
RXRX income_statement (quarterly, 2025-09-30) — Basic EPS: -0.36
RXRX cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 533845000.00
RXRX cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -243000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 61553000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Capital Stock: 5000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 659836000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 659836000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 223161000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Cash Financial: 436675000.00
RXRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 251340000.00
RXRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -2549000.00
RXRX cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -117360000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -5890000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: -12088000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -5216000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -6631000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Payable: -5890000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -17978000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 0.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Receivables: 3529000.00
RXRX cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -26296000.00
RXRX cash_flow (quarterly, 2025-09-30) — Changes In Cash: 131431000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Common Stock: 5000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 1046948000.00
RXRX cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 254460000.00
RXRX income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 14687000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 49304000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Assets: 714105000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 11525000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Debt: 8919000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 20444000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 47364000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 47364000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 155103000.00
RXRX cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 21043000.00
RXRX cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 21043000.00
RXRX income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 446988046.00
RXRX income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.36
RXRX income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — EBIT: -161417000.00
RXRX income_statement (quarterly, 2025-09-30) — EBITDA: -140374000.00
RXRX cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 1869000.00
RXRX cash_flow (quarterly, 2025-09-30) — End Cash Position: 667145000.00
RXRX cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 251340000.00
RXRX cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -117603000.00
RXRX cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 34093000.00
RXRX income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 41628000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Goodwill: 162042000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 484386000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Gross PPE: 181244000.00
RXRX income_statement (quarterly, 2025-09-30) — Gross Profit: -9704000.00
RXRX income_statement (quarterly, 2025-09-30) — Interest Expense: 833000.00
RXRX income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 833000.00
RXRX income_statement (quarterly, 2025-09-30) — Interest Income: 5540000.00
RXRX income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 5540000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Invested Capital: 1067769000.00
RXRX cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -2549000.00
RXRX cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 254460000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 50028000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 11902000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 61930000.00
RXRX cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -2127000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 254460000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -162253000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -162253000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -162253000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: 0.00
RXRX income_statement (quarterly, 2025-09-30) — Net Interest Income: 4707000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -2306000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -2127000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -2127000.00
RXRX income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 4707000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 0.00
RXRX balance_sheet (quarterly, 2025-09-30) — Net PPE: 181244000.00
RXRX cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -243000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 562562000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 134516000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 111204000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 23312000.00
RXRX income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -140374000.00
RXRX income_statement (quarterly, 2025-09-30) — Normalized Income: -162253000.00
RXRX cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -117360000.00
RXRX cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 22082000.00
RXRX income_statement (quarterly, 2025-09-30) — Operating Income: -172202000.00
RXRX income_statement (quarterly, 2025-09-30) — Operating Revenue: 4983000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 491800501.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 29223000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 8919000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 34093000.00
RXRX income_statement (quarterly, 2025-09-30) — Other Gand A: 41628000.00
RXRX income_statement (quarterly, 2025-09-30) — Other Income Expense: 5245000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 322344000.00
RXRX cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 2821000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 18834000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 1029000.00
RXRX income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 5245000.00
RXRX income_statement (quarterly, 2025-09-30) — Other Operating Expenses: -192000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Properties: 181244000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Other Receivables: 21910000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Payables: 13935000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 63239000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 24056000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 0.00
RXRX income_statement (quarterly, 2025-09-30) — Pretax Income: -162250000.00
RXRX cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: -993000.00
RXRX cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
RXRX cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: 0.00
RXRX cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -2306000.00
RXRX cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -243000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Receivables: 21910000.00
RXRX income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 14687000.00
RXRX income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 21043000.00
RXRX cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -2127000.00
RXRX income_statement (quarterly, 2025-09-30) — Research And Development: 121062000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 3136000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -1967879000.00
RXRX income_statement (quarterly, 2025-09-30) — Selling General And Administration: 41628000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Share Issued: 491800501.00
RXRX cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 25243000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 1046948000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 562562000.00
RXRX income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (quarterly, 2025-09-30) — Tax Provision: 3000.00
RXRX income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
RXRX balance_sheet (quarterly, 2025-09-30) — Total Assets: 1399526000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 1058850000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Debt: 82374000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 1046948000.00
RXRX income_statement (quarterly, 2025-09-30) — Total Expenses: 177185000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 352578000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 685421000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 197475000.00
RXRX income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -172202000.00
RXRX balance_sheet (quarterly, 2025-09-30) — Working Capital: 559002000.00
RXRX income_statement (annual, 2025-12-31) — +Operating Expense: 651435000.00
RXRX income_statement (quarterly, 2025-12-31) — +Operating Expense: 129410000.00
RXRX income_statement (annual, 2025-12-31) — +Total Revenue: 74256000.00
RXRX income_statement (quarterly, 2025-12-31) — +Total Revenue: 35351000.00
RXRX balance_sheet (annual, 2025-12-31) — Accounts Payable: 18118000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 18118000.00
RXRX balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -89214000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -89214000.00
RXRX balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 3170145000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 3170145000.00
RXRX cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 5956000.00
RXRX cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
RXRX income_statement (annual, 2025-12-31) — Basic Average Shares: 447446109.00
RXRX income_statement (quarterly, 2025-12-31) — Basic Average Shares: 526719743.00
RXRX income_statement (annual, 2025-12-31) — Basic EPS: -1.44
RXRX income_statement (quarterly, 2025-12-31) — Basic EPS: -0.21
RXRX cash_flow (annual, 2025-12-31) — Beginning Cash Position: 603024000.00
RXRX cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 667145000.00
RXRX cash_flow (annual, 2025-12-31) — Capital Expenditure: -8627000.00
RXRX cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1244000.00
RXRX balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 59310000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 59310000.00
RXRX balance_sheet (annual, 2025-12-31) — Capital Stock: 5000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Capital Stock: 5000.00
RXRX balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 743294000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 743294000.00
RXRX balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 743294000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 743294000.00
RXRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 521532000.00
RXRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 132006000.00
RXRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -16871000.00
RXRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -1244000.00
RXRX cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -371808000.00
RXRX cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -46073000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Account Payable: -2616000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 4419000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -9735000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: -2537000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -19988000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -3864000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -36771000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -6757000.00